EA025232B1 - Композиции для лечения нервных расстройств - Google Patents

Композиции для лечения нервных расстройств Download PDF

Info

Publication number
EA025232B1
EA025232B1 EA201391407A EA201391407A EA025232B1 EA 025232 B1 EA025232 B1 EA 025232B1 EA 201391407 A EA201391407 A EA 201391407A EA 201391407 A EA201391407 A EA 201391407A EA 025232 B1 EA025232 B1 EA 025232B1
Authority
EA
Eurasian Patent Office
Prior art keywords
patients
approximately
group
acid
treatment
Prior art date
Application number
EA201391407A
Other languages
English (en)
Russian (ru)
Other versions
EA201391407A1 (ru
Inventor
Панцарис Мариос
Патрикиос Иоаннис
Лукаидис Георгиос
Original Assignee
Палупа Медикал Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46275907&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA025232(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Палупа Медикал Лтд. filed Critical Палупа Медикал Лтд.
Publication of EA201391407A1 publication Critical patent/EA201391407A1/ru
Publication of EA025232B1 publication Critical patent/EA025232B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EA201391407A 2011-03-29 2012-03-28 Композиции для лечения нервных расстройств EA025232B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161469081P 2011-03-29 2011-03-29
PCT/IB2012/000824 WO2012131493A1 (en) 2011-03-29 2012-03-28 Compositions for the treatment of neurologic disorders

Publications (2)

Publication Number Publication Date
EA201391407A1 EA201391407A1 (ru) 2014-03-31
EA025232B1 true EA025232B1 (ru) 2016-12-30

Family

ID=46275907

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391407A EA025232B1 (ru) 2011-03-29 2012-03-28 Композиции для лечения нервных расстройств

Country Status (20)

Country Link
US (2) US20120252888A1 (OSRAM)
EP (1) EP2691086B1 (OSRAM)
JP (1) JP6092843B2 (OSRAM)
CN (1) CN104010634B (OSRAM)
AU (1) AU2012235869B2 (OSRAM)
BR (1) BR112013025088B1 (OSRAM)
CA (1) CA2831506C (OSRAM)
CY (1) CY1117828T1 (OSRAM)
DK (1) DK2691086T3 (OSRAM)
EA (1) EA025232B1 (OSRAM)
ES (1) ES2585066T3 (OSRAM)
GE (1) GEP201606568B (OSRAM)
HR (1) HRP20160939T1 (OSRAM)
HU (1) HUE028065T2 (OSRAM)
IL (1) IL228541A (OSRAM)
MX (1) MX2013011295A (OSRAM)
PL (1) PL2691086T3 (OSRAM)
UA (1) UA114706C2 (OSRAM)
WO (1) WO2012131493A1 (OSRAM)
ZA (1) ZA201307256B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709680B2 (en) * 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
ITMI20130354A1 (it) * 2013-03-08 2014-09-09 Again Life Italia Srl Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.
CN105828816A (zh) * 2013-11-12 2016-08-03 雅培公司 包含天然维生素e和多不饱和脂肪酸的营养组合物的用途
KR102400958B1 (ko) 2014-06-06 2022-05-20 마린 인그리디언츠, 엘엘씨 오메가-3 조성물, 제형 및 사용 방법
JP2018518451A (ja) * 2014-11-07 2018-07-12 マゼ ジョリー ヴァダケムリ 最適化された栄養分の脂肪酸組成
DE102015109352A1 (de) * 2015-06-12 2016-12-15 K. D. Pharma Bexbach Gmbh Anwendung von Omega-3- und/oder Omega-6-Fettsäure(n)
AR102008A1 (es) * 2015-09-24 2017-01-25 Brix S R L Ingrediente farmacéutico activo (ifa) oleoso para el tratamiento de afecciones de la piel, composiciones que lo comprenden y su uso para prepararlas
WO2017213490A1 (en) 2016-06-10 2017-12-14 N.V. Nutricia Method for controlling neuroinflammation
BR112019008739A2 (pt) 2016-11-04 2019-07-09 Immd Sp Zo O distribuição inteligente de moléculas ingeridas e absorvidas
CN109125311A (zh) * 2018-06-26 2019-01-04 东南大学 预防或治疗阿尔茨海默症的药物组合物及其应用
WO2022170226A1 (en) * 2021-02-08 2022-08-11 Synaptogenix, Inc. Treatment of optic nerve inflammation using pkc activators
US20240180869A1 (en) * 2021-02-08 2024-06-06 Synaptogenix, Inc. Treatment of multiple sclerosis using pkc activators
US12048681B2 (en) * 2021-08-09 2024-07-30 Kentucky Equine Research, Inc. Compositions and methods for modulating equine fatty acid profiles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0234733A1 (en) * 1986-01-27 1987-09-02 Scotia Pharmaceuticals Limited Pharmaceutical compositions
EP0440341A1 (en) * 1990-01-18 1991-08-07 Scotia Holdings Plc EFA compositions and therapy
EP0520624A1 (en) * 1991-06-03 1992-12-30 Scotia Holdings Plc Nutritional, pharmaceutical and cosmetic compositions containing di-linoleoyl-mono-gamma-linolenyl-glycerol
WO1996031457A1 (en) * 1995-04-03 1996-10-10 Scotia Holdings Plc Triglycerides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601399D0 (en) * 1986-01-21 1986-02-26 Delta Iota Ltd Information transmission/processing
GB8813766D0 (en) 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
PH31403A (en) * 1991-03-01 1998-10-29 Warner Lambert Co Therapeutic compositions to protect and recuscitate mammalian cells and methods for preparing same.
JP3283274B2 (ja) * 1991-06-15 2002-05-20 サントリー株式会社 新規組成物
DE19757414A1 (de) * 1997-12-23 1999-07-01 Nutricia Nv Fettmischung
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US6677321B1 (en) * 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
US7045683B2 (en) 2001-05-04 2006-05-16 Abbott Laboratories Δ4-desaturase genes and uses thereof
DE60203494T2 (de) * 2001-05-30 2006-02-09 Laxdale Ltd. Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
PT1417211E (pt) 2001-07-27 2007-08-28 Neptune Technologies & Bioress Fosfolípidos naturais de origem marinha contendo flavonóides e fosfolípidos polinsaturados e suas utilizações.
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
US20050080109A1 (en) 2003-10-09 2005-04-14 Papas Andreas M. Gamma-tocopherol and gamma-tocotrienol therapy for multiple sclerosis
NZ569676A (en) * 2005-12-21 2012-03-30 Brudy Technology S L Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
US20090196862A1 (en) * 2008-01-22 2009-08-06 William Davis High dosage Vitamin D
JP2010155799A (ja) * 2008-12-26 2010-07-15 Fujifilm Corp 粉末組成物及びそれを含む食品
WO2010118761A1 (en) * 2009-04-17 2010-10-21 Eolas Science Limited Compositions rich in omega-3 fatty acids with a low content in phytanic acid

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0234733A1 (en) * 1986-01-27 1987-09-02 Scotia Pharmaceuticals Limited Pharmaceutical compositions
EP0440341A1 (en) * 1990-01-18 1991-08-07 Scotia Holdings Plc EFA compositions and therapy
EP0520624A1 (en) * 1991-06-03 1992-12-30 Scotia Holdings Plc Nutritional, pharmaceutical and cosmetic compositions containing di-linoleoyl-mono-gamma-linolenyl-glycerol
WO1996031457A1 (en) * 1995-04-03 1996-10-10 Scotia Holdings Plc Triglycerides

Also Published As

Publication number Publication date
BR112013025088A2 (pt) 2017-02-14
MX2013011295A (es) 2014-11-10
EP2691086B1 (en) 2016-04-27
CN104010634B (zh) 2017-06-09
DK2691086T3 (en) 2016-08-15
UA114706C2 (uk) 2017-07-25
GEP201606568B (en) 2016-11-10
US20190343774A1 (en) 2019-11-14
JP6092843B2 (ja) 2017-03-08
ZA201307256B (en) 2014-12-23
HRP20160939T1 (hr) 2016-10-07
PL2691086T3 (pl) 2016-12-30
HK1194665A1 (zh) 2014-10-24
CN104010634A (zh) 2014-08-27
AU2012235869B2 (en) 2017-04-20
JP2014512351A (ja) 2014-05-22
BR112013025088B1 (pt) 2021-12-14
HUE028065T2 (en) 2016-11-28
CA2831506A1 (en) 2012-10-04
WO2012131493A1 (en) 2012-10-04
NZ616554A (en) 2015-10-30
US20120252888A1 (en) 2012-10-04
ES2585066T3 (es) 2016-10-03
EP2691086A1 (en) 2014-02-05
AU2012235869A1 (en) 2013-10-17
CA2831506C (en) 2019-07-09
EA201391407A1 (ru) 2014-03-31
IL228541A0 (en) 2013-12-31
IL228541A (en) 2017-11-30
CY1117828T1 (el) 2017-05-17

Similar Documents

Publication Publication Date Title
EA025232B1 (ru) Композиции для лечения нервных расстройств
EP1275399B1 (en) Method and preparation for preventing and/or treating vascular disorders and secondary disorders associated therewith
US20080009467A1 (en) Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US8283336B2 (en) Unit dosage for brain health
US12115137B2 (en) Synergistic combinations of atorvastatin and cannabidiol (CBD)
KR20190085973A (ko) 동위원소로 변형된 성분 및 이의 치료학적 용도
EP1852114B1 (en) Composition containing dihomo-y-linolenic acid (dgla) as active ingredient
WO2009005519A1 (en) Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
JP2007153845A (ja) 脂肪蓄積抑制剤
US11110113B2 (en) Compositions and methods for treating depression
NZ616554B2 (en) Compositions for the treatment of neurologic disorders
HK1194665B (en) Compositions for the treatment of neurologic disorders
US20150133554A1 (en) Purification of dpa enriched oil
WO2024089586A1 (en) Compositions comprising acetic acid, butyric acid and quercetin and uses thereof
WO2007084648A2 (en) Mixed 4→6 procyanidin dimers and their use
HK1051975B (en) Method and preparation for preventing and / or treating vascular disorders and secondary disorders associated therewith

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG MD TJ

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ KZ TM